CALLIDITAS THERAPEUTICS AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 39.99 USD | +3.95% |
|
+78.37% | +55.34% |
| May. 31 | Citigroup Downgrades Calliditas Therapeutics to Neutral From Buy, Price Target at $39 | MT |
| May. 31 | Calliditas Partner Secures European Panel Backing for Rare Kidney Disease Treatment | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Sector Specialty & Advanced Pharmaceuticals
| Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E ratio | |
|---|---|---|---|---|---|---|
| 78.51B | ||||||
| 9B | ||||||
| 4.96B | - | - | ||||
| 4.84B | ||||||
| 3.72B |
